It is a prime concern of Evotec that all relevant target groups receive the same information at the same time. This implies communicating in both English and German.

Please find below the most recent corporate news, ad hoc releases and other announcements of our Company.

 

2018

Evotec forms academic BRIDGE 'LAB591’ with Arix Bioscience and Fred Hutchinson Cancer Research Center
Nerina Coppini, 31 May 2018

Combination of one of the premier cancer research centers with a strong company builder and Evotec's drug discovery expertise to create and support new companies focused on therapeutic breakthroughs for patients in the areas of oncology and infectious diseases Expands Evotec's academic ‘BRIDGE’ initiative under EVT INNOVATE Initial term of...

 

Other announcements

Merger

The following annoucement has been published in the German Federal Gazette in accordance with the German Conversion Act (Umwandlungsgesetz) in 2013. Pursuant to the German Conversion Act, certain transaction intended by Evotec AG, e.g. up-stream mergers, have to be announced in the Federal Gazette (Bundesanzeiger).

Contact us

Gabriele Hansen

VP, Corporate Communications & Investor Relations

T +49 40 560 81 255 F +49 40 560 81 333 vCard

Katja Werner

Investor Relations Associate

T +49 40 560 81 210 F +49 40 560 81 333 vCard